We are international
• about myeloma TEXT SIZE   
publications    back

Myeloma Minute
August 7, 2014
August 7, 2014
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

This week's question: Is it okay to take vitamin B12 on the same day as Velcade?

Upcoming Events

August 22 - 23, 2014
Patient & Family Seminar
Los Angeles, California

Saturday, August 23, 2014
A Day at the Races
Oceanport, New Jersey

Thursday, August 28, 2014
Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma

Cancer Cases Among 9/11 Early Responders Continue to Grow

More cancer cases are being reported among 9/11 rescuers and responders, with more than 2,500 people with cancer now included in World Trade Center health programs. Myeloma is covered under the 9/11 Victim Compensation Fund, and studies have shown that 9/11 workers have gotten myeloma at a higher rate than expected in the normal population. Research has also shown a relationship between myeloma and exposure to carcinogens located at the World Trade Center site. IMF Chairman Dr. Brian Durie has written extensively on myeloma and toxins, and in his blog this week, he examines this troubling growth in cases. READ MORE

Encouraging Results in Kyprolis Late-Stage Clinical Trial

Initial results from a phase III clinical trial have shown that treatment with the combination of Kyprolis, Revlimid, and low-dose dexamethasone extended progression-free survival (PFS) for relapsed myeloma patients compared to treatment with Revlimid and low-dexamethasone alone. At an interim analysis, the median PFS (or time until myeloma progressed) was slightly over two years in the Kyprolis arm compared with nearly 18 months in the Revlimid/dexamethasone-only arm. Full data from this clinical trial are expected at the 2014 American Society of Hematology Annual Meeting in December. READ MORE

Key Myeloma Research from Scientific Meetings Highlighted in Myeloma Today
The summer 2014 edition of the IMF's Myeloma Today is available online and filled with news from the global myeloma community. The issue includes a detailed report on the 5th Annual Summit of the International Myeloma Working Group (IMWG) and highlights the most important myeloma presentations from the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Also included is a special letter from IMF President Susie Novis honoring IMF board member Mike Katz, recipient of ASCO’s Partners in Progress Award. READ MORE
Maine Oral Anticancer Treatment Law Takes Effect
Maine cancer patients are assured affordable access to their oral anticancer drugs thanks to the work of the IMF and other organizations on a new law that went into effect on August 1st. The law requires health benefit plans that already cover IV or injected anticancer medications to cover oral therapies at the same level. “It’s encouraging to see states recognize that policy needs to keep pace with medical advances that offer lifelines to patients who have exhausted other treatments,” said Susie Novis. CLICK HERE for an NPR story. READ MORE



Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe 

 related articles